Articles tagged with Parkinsons Disease
A team of McMaster researchers is using tiny worms and microtechnology to search for effective new drugs to treat Parkinson's disease. They hope to accelerate the process of drug discovery, which could have direct application to human health.
Researchers at Buck Institute discover lithium profoundly prevents brain damage associated with Parkinson's disease in a mouse model. The study's findings suggest that lithium could be an effective treatment for PD patients at subclinical levels, avoiding side effects.
The study discovered two novel genetic associations with Parkinson's disease, one near the SCARB2 gene and another near SREBF1 and RAI1 genes. The research also replicated twenty previously known genetic associations, providing strong evidence for the web-based design used in this study.
A new iPhone application, iTrem, has been developed to track hand and arm tremors in patients with Parkinson's disease. The app uses the iPhone's accelerometer to collect data, which can be used by physicians to remotely monitor patient disability and treatment response.
A study by Massachusetts General Hospital researchers reveals that disruption of the molecular pathway causing Gaucher disease leads to toxic α-synuclein deposits in Parkinson's disease. This finding indicates therapies targeting this pathway may be a new option for patients with Parkinson's disease.
Researchers discovered a molecular link between pesticides and Parkinson's disease, shedding light on the oxidative stress that contributes to the neurodegenerative disorder. The study provides evidence that exposure to environmental toxins may be a primary cause of Parkinson's, with potential implications for prevention and treatment.
A genome-wide association study found three SNPs associated with PSP, suggesting they may contribute to disease susceptibility. These genes are involved in tau protein regulation and membrane recycling.
Researchers at USC have found that the energy difference between two alpha-synuclein structures is less than previously thought, offering new insights into the protein's role in Parkinson's disease. This discovery could help explain why the protein misfolds and becomes toxic to surrounding nerve cells.
Researchers have identified why dopamine replacement therapy has a negative effect on cognition in Parkinson's disease patients. The study found that the treatment enhances functions of the dorsal striatum at the expense of the ventral striatum.
Researchers at North Carolina State University have figured out how copper induces misfolding in the protein associated with Parkinson's disease. This finding has implications for both the study of Parkinson's progression and future treatments. The researchers used computer simulations to ferret out the most likely binding scenario, re...
Researchers found that people with Parkinson's disease are twice as likely to develop melanoma, a deadly form of skin cancer. Women with Parkinson's disease are also at higher risk, particularly for aggressive forms of the disease.
Neurologix presents 1-year data from its Phase 2 study of NLX-P101, a gene therapy for Parkinson's disease, showing sustained improvements in motor symptoms. Patients treated with NLX-P101 experienced highly clinically meaningful symptom improvements, with a mean 37% improvement after one year.
Researchers found that combined exposure to the three chemicals increases the risk of Parkinson's disease threefold. People who live and work near fields sprayed with these pesticides experience the greatest increase in risk.
A study found that infection with the bacteria Helicobacter pylori can lead to Parkinson's disease symptoms in mice, and researchers suggest that this may be due to a modified cholesterol produced by the bacteria. The findings could have implications for understanding the development of neurodegenerative disorders.
The One Mind for Research Forum aims to dramatically advance the understanding and treatment of brain disorders, including Parkinson's disease. Researchers will share latest findings on neurodegenerative diseases, and a 10-year research agenda will be endorsed.
Researchers have identified a stem cell population that can reverse nerve cell loss in individuals with Parkinson disease. Protein-based human induced pluripotent stem (iPS) cells were found to efficiently generate functional dopamine neurons and treat a rat model of the disease. These findings suggest a potential new treatment approac...
Researchers have identified stem cell population that can reverse nerve cell loss in individuals with Parkinson disease. Protein-based human iPS cells efficiently generate functional dopamine neurons and treat a rat model of the disease.
A new study suggests that disrupting the supply chain of nerve cells may contribute to Parkinson's disease. Researchers found that a drug called MPP+ damages mitochondria, which can't be transported to axons, leading to cell death.
A new study suggests that group doctor visits could be an effective way to manage Parkinson's disease, allowing patients more time with their doctors and providing education on managing the condition. The study found no difference in quality of life between those receiving usual care and those participating in group visits.
Researchers identify small molecule blocking key protein involved in cholesterol production, successfully lowering cholesterol levels in isolated nerve cells and brain slices from mice. The discovery could lead to broader applications in other neurological conditions like Alzheimer's disease.
Researchers at the University of Maryland found that low-intensity exercise, such as walking on a treadmill for 50 minutes three times a week, can improve mobility and delay disability in Parkinson's patients. The study also showed benefits from stretching and resistance exercises.
A new clinical trial shows that safinamide can help patients with severe Parkinson's disease by reducing dyskinesia, or movement problems. The study found that taking safinamide in addition to levodopa and other dopaminergic treatments reduced dyskinesia by 24% in some participants.
A randomized trial comparing three types of exercise training found that low-intensity treadmill exercise resulted in the most consistent improvements in gait and mobility for people with Parkinson's disease. Stretching and resistance exercises also showed some benefits.
Researchers found that welders had an average 11.7 percent reduction in dopamine markers in the brain compared to non-welders, suggesting potential neurotoxic effects from manganese exposure. The study also revealed brain changes consistent with manganese deposits, highlighting a potential public health concern for U.S. workers.
A study published in Neurology found that welders exposed to welding fumes had an average 11.7% reduction in dopamine levels in the brain, indicating potential neurotoxic effects. The researchers also discovered brain changes consistent with manganese deposits in welders.
A Canadian-led international study has found a link between the most common genetic risk factor for Parkinson's and the hallmark accumulation of alpha-synuclein in the brains of people with Parkinson's. The GBA mutation increases the risk of developing Parkinson's symptoms four to five years earlier than those without it.
The discovery of the Skywalker enzyme reveals a crucial step in vesicle recycling, leading to improved signal transmission and potentially new diagnostics and therapies for Parkinson's disease. Understanding this process may help maintain optimal communication balance between brain cells.
Earlier deep brain therapy shows better, quicker results for patients with potentially crippling dystonia. A study found that those treated earlier have better general outcomes, while age at surgery influences the time necessary to achieve optimal benefit.
Researchers found that Parkinson's sufferers exhibited work and health indications eight years before diagnosis, highlighting REM sleep behavior disorder as a potential early marker. The study suggests that intervening earlier could lead to improved treatment outcomes.
A double-blind gene therapy trial has demonstrated safety and significant improvement in motor function for patients with Parkinson's disease. The study found that injecting the glutamic acid decarboxylase (GAD) gene directly into the brain improved motor scores by 23.1% compared to a placebo group.
A gene therapy called NLX-P101 significantly reduces movement impairment in Parkinson's patients, with half achieving dramatic symptom improvements. The treatment introduces a gene to normalize chemical signaling, correcting dysfunction in brain circuitry responsible for coordinating movement.
A new study found that gene therapy NLX-P101 improved motor performance and control of Parkinsonism symptoms in half of patients, offering hope for the treatment of neurodegenerative disorders. The therapy has been safe and well-tolerated over a six-month period.
A double-blind trial demonstrated a 23% improvement in motor symptoms among patients receiving gene therapy for advanced Parkinson's disease, compared to a 12% improvement in those receiving sham surgery. The study suggests a potential breakthrough in treating this progressive movement disorder.
A recent study published in Archives of Neurology reveals a high prevalence of vitamin D insufficiency among patients with early Parkinson's disease. Contrary to expectations, the researchers found that vitamin D concentrations remained stable over time, suggesting a potential role for long-term insufficiency in the pathogenesis of PD.
Researchers found that eliminating caspase-2 prolongs the life of neurons stressed by pesticide chemicals, a potential therapeutic target for neurodegenerative disorders like Parkinson's and Alzheimer's diseases. Neurons lacking caspase-2 increase autophagy to survive.
Abnormal neural activity was recorded from the deep brain of Parkinson's disease and dystonia patients, confirming previous animal study results. The findings suggest that cortically evoked neural responses in the basal ganglia can be used to determine target locations for deep brain stimulation electrodes.
Researchers at Rush University Medical Center are testing a gene therapy product called CERE-120 to evaluate its effectiveness in reducing symptoms of Parkinson's disease. The treatment involves delivering the human gene for neuturin directly to degenerating dopamine neurons in the brain.
Researchers at the University of Colorado School of Medicine have discovered a drug that turns on a protective gene, protecting brain cells from degeneration. The drug, phenylbutyrate, has been shown to prevent the progression of Parkinson's disease in mice and is now being tested in humans.
Researchers at Stanford University School of Medicine successfully derived neurons with symptoms of Parkinson's disease from a patient's skin cells. These neurons exhibit key features of the condition, including oxidative stress and Lewy body formation, in a short timeframe.
Researchers found that PARIS protein accumulates in brain cells with mutated parkin gene, leading to decreased PGC-1alpha levels and neurodegeneration. This discovery offers promising new drug targets to slow or stop Parkinson's disease progression.
Research suggests ibuprofen may protect against Parkinson's disease by targeting a specific receptor in the brain. Taking ibuprofen regularly reduced the risk of developing the disease by 38%, according to the study published in Neurology.
A new Harvard School of Public Health study found that adults who regularly take ibuprofen have a lower risk of developing Parkinson's disease. The researchers analyzed data from nearly 99,000 women and 37,000 men, finding that ibuprofen use was associated with a 38% reduced risk of Parkinson's disease.
Researchers at Iowa State University have discovered a protein pathway that may hold the key to understanding and treating Parkinson's disease. By modifying the production of a specific protein, they believe it is possible to inhibit the destructive effects on dopamine-producing cells.
Using amphetamines like Benzedrine and Dexedrine may increase the risk of developing Parkinson's disease, according to a new study. The research, which followed 66,348 participants in northern California, found that those who used these drugs were nearly 60% more likely to develop the condition.
Researchers discovered a strong link between the use of pesticides rotenone and paraquat and an increased risk of developing Parkinson's disease. The study found that people who used these pesticides developed the disease around 2.5 times more often than non-users.
Researchers at Emory University School of Medicine found that a protein called MEF2D plays a key role inside mitochondria in brain cells, and its impairment is linked to Parkinson's disease progression. The study suggests that problems with MEF2D could represent one of the earliest steps in neurodegeneration.
A study published in Neurology found that men who eat berries regularly have a lower risk of developing Parkinson's disease. Flavonoids, particularly anthocyanins from berries, were associated with a reduced risk in both men and women.
Researchers found that a naturally present brain chemical signal, CX3CL1, can suppress microglial activation and reduce inflammation in an animal model of Parkinson's disease. This suggests that the communication between neurons and glial cells may play a role in neurodegeneration.
A new compound has shown significant effectiveness in protecting brain cells directly affected by Parkinson's disease, a progressive and fatal neurodegenerative disorder. The compound, SR-3306, aims to inhibit JNK enzymes that play a key role in neuron survival.
Preladenant significantly reduces off time and increases on time without worsening dyskinesia in Parkinson's disease patients. The study found that preladenant may offer a new supplemental treatment option for patients experiencing 'wearing off' symptoms from levodopa therapy.
SLU researchers found that DOPAL kills healthy dopamine cells, leading to Parkinson's disease. The study provides a promising new avenue for preventing dopamine neuron loss and progression of the disease.
A groundbreaking study found that mesenchymal stem cells delivered through the nose improved motor function and increased dopamine levels in rats with Parkinson's disease. This non-invasive approach offers a safer alternative to surgical transplantation.
Researchers aim to replicate Parkinson's disease in lab cells and investigate inflammation to find new therapies. Led by Fred H. Gage, the team will use human induced pluripotent stem cells derived from patients to study neurodegeneration.
Researchers have identified five additional genetic variations that contribute significantly to Parkinson's disease risk, with 20% of patients carrying high-risk variants being two-and-a-half times more likely to develop PD. The study highlights the importance of common genetic variation in the development of this debilitating condition.
Loyola University Health System neurologists Dr. José Biller and Dr. Michael J. Schneck predict an 'explosive growth in potential medical therapies' for age-related neurological disorders. New treatments and diagnostic tests have led to an increased demand for neurologists and interest in the field.
A recent study suggests that damaged alpha-synuclein proteins can spread between cells in a 'prion-like' manner, contributing to Parkinson's disease pathogenesis. This cell-to-cell transfer mechanism may play a significant role in the progression of neurodegenerative diseases.
A new study by Michele Tagliati and colleagues found that patients with deep brain stimulation experienced no significant progression of motor symptoms over five years. The research suggests that the therapy may actually stabilize these symptoms, challenging previous assumptions about Parkinson's disease progression.
Researchers identify a key process leading to brain cell death in Parkinson's disease, offering hope for slowing progression and diagnosis. Blocking this process preserves parkin function and spares neurons.
A recent study from the University of Maryland School of Medicine found that African American patients and those with lower socioeconomic status have more advanced Parkinson's disease and greater disability when seeking treatment from specialists. This disparity is associated with earlier loss of independence and greater disease severity.
A study found that African American patients with Parkinson's disease have more severe parkinsonism and greater disability compared to white patients. Lower socioeconomic status is also associated with increased disease severity and reduced access to effective treatments, such as newer dopaminergic medications.